Healthcare

Retatrutide Data Signals New Era in Obesity Treatment Economics as Lilly Distances From GLP-1 Competition

Eli Lilly's next-generation obesity drug retatrutide delivered impressive safety data in late-stage trials, positioning the pharmaceutical giant to potentially dominate a weight-loss market projected to reach $100 billion by 2030. The promising results could reshape competitive dynamics in a sector where current treatments face supply constraints and pricing pressures.